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analysis showed no relationship between cosmetic result and 
age (p>0.13). 
 
Conclusion: Our experiences is limited to a low number of 
cases but confirm that adjuvant radiotherapy is not 
controindicated when reconstructive surgery is expected. The 




Phase II trial of hypofractionated VMAT treatment for early 
stage breast cancer: 2-years outcomes 
F. De Rose
1Istituto Clinico Humanitas, Radiotherapy and Radiosurgery, 
Rozzano Milan, Italy 
1, D. Franceschini1, A. Fogliata1, C.S. Iftode1, E. 
Villa1, A.M. Ascolese1, P. Navarria1, C. Franzese1, T. Comito1, 
A. Tozzi1, E. Clerici1, R.L.E. Liardo1, F. Lobefalo1, G.R. 
D'Agostino1, M. Scorsetti1 
 
Purpose or Objective: To report 2-years toxicity and clinical 
results of hypofractionated simultaneous integrated boost 
(SIB) tecnique with Volumetric Modulated Arc Therapy 
(VMAT) as adjuvant treatment after breast-conserving 
surgery. 
 
Material and Methods: Patients presenting early-stage breast 
cancer were enrolled in a phase II trial. Eligibility criteria: 
age>18 years, invasive cancer or DCIS, Stage I-II (T<3 cm and 
N≤3), breast-conserving surgery without oncoplastic 
reconstruction, any systemic therapy was allowed in 
neoadjuvant or adjuvant setting. All patients underwent 
VMAT-SIB technique to irradiate the whole breast and the 
tumor bed. Doses to whole breast and surgical bed were 
40.5Gy and 48Gy, respectively, delivered in 15 fractions over 
3 weeks. Acute and late skin toxicities were recorded based 
on RTOG scoring criteria and CTCAE v. 4.0, respectively. 
Cosmetic outcome was assessed as excellent/good or 
fair/poor, according to the Harvard scale. 
 
Results: The present study focused on long-term results of a 
cohort of 144 patients with a minimum follow-up of 24 
months (median 37, range 24-55 months). Median age was 62 
y.o. (range 30-88). At one year, the highest reported skin 
toxicity was G1, in 14% of the patients; this data dropped to 
4% at the last follow-up, after more than 2 years. Breast pain 
was recorded in 21.6% of the patients 6 months after 
treatment, while it was present in 3.5% of the patients at the 
last follow-up, showing a significant improvement with time. 
No correlation with liponecrosis as recorded from ultrasound 
exam, nor with dosimetric data. Skin toxicity was correlated 
with breast volume. No pulmonary or cardiological toxicities 
were recorded. After an early evaluation of clinical 
outcomes, only one case presented disease relapse, as liver 
metastases. 
 
Conclusion: The hypofractionated VMAT-SIB course as 
adjuvant treatment after breast-conserving surgery showed 
to be safe and effective with optimal local control. This 
approach requires validation with long-term follow-up data. 
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Purpose or Objective: To investigate the impact of the boost 
dose escalation on ipsilateral breast tumor recurrence (IBTR), 
for breast cancer patients with involved surgical margins 
after breast conserving surgery. 
 
Material and Methods: Between January 1998 and December 
2010 at Asan Medical center, among 4275 breast cancer 
patients who were treated with breast conserving therapy 
(BCT), a total 192 patients were treated with boost dose over 
10 Gy for involved resection margin. We retrospectively 
analyzed the outcomes in 192 patients who had whole breast 
irradiation of 50.4 Gy followed by median boost dose 15.0 Gy 
(range, 12 - 16 Gy) for breast cancer with involved resection 
margin. Surgery preceded referral for radiotherapy with a 1-2 
mm margin of macroscopically normal tissue. The resection 
margins were evaluated by pathologist for the presence of 
invasive carcinoma or ductal carcinoma in situ at the inked 
margin. Neoadjuvant chemotherapy was done in 3 patients 
(1.6 %). Adjuvant chemotherapy was given in 93 patients 
(48.4%). 157 patients (81.8%) received systemic hormone 
therapy. The median age was 46 years (range, 25-73 years). 
182 patients (94.8%) were stage 0 to II and 10 patients (5.2%) 
with stage III breast cancer were also included. The boost 
dose delivered with electrons or tangential fields given in 
daily fractions of 1.5 to 2.5 Gy. The boost volume was 
described as the site of the primary tumor with a margin of 
1.5 cm to the field borders after breast conserving surgery. 
 
Results: The median follow-up duration for all patients was 
6.7 years. IBTR were considered as any local failures on 
ipsilateral breast regardless of the location. The 5-year 
cumulative risk of ipsilateral breast tumor recurrence as a 
first event was 5.4%. The 5-year local relapse free survival 
(LRFS) was 94.4%. IBTR occurred as a first failure in 13 of 192 
patients. In boost field recurrences were found in 11 patients 
(85%). 5 patients (39 %) were out-of boost field failures and 3 
of them were both failures. On univariate analysis, age, cell 
type, pT stage, pN stage, extensive intraductal component 
(EIC), multiplicity and location of resection margin were 
prognostic factor for IBTR (p <0.05). In multivariate analysis 
only young age (<40 years old) and positive radial resection 
margin were unfavorable prognostic factor for LRFS (p 
=0.037, p=0.021 respectively). pT stage was marginally 
significant prognostic factor for IBTR. (p=0.088) 
 
Conclusion: Median boost dose of 15 Gy is comparable to 
historical boost research results for local control in breast 
cancer patients with involved resection margin after BCT. 
Young age (<40 years old) and positive radial resection 
margin rather than superficial or deep margin were important 
risk factors for ipsilateral breast tumor recurrence. More than 
80% of local recurrences were in boost field, more boost dose 
escalation needs to be considered. 
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Purpose or Objective: Cancer-related fatigue is one of most 
prevalent symptom among women submitted to radiotherapy 
(RT) for breast cancer (BC). Despite its prevalence the 
mechanism of onset is unknown still: one possible mechanism 
is activation of the immune system, through the mediation by 
proinflammatory cytokines interleukin (IL), IL1-b,, IL-6, and 
tumor necrosis factor-a (TNF-a) as host response to tissue 
damage determined by the radiant treatment. To purpose of 
this study was to determine the level of fatigue in a group of 
BC patients its relation to anxiety, depression, serum 
cytokines, cortisol and blood count levels 
 
Material and Methods: Between October 2013 and May 2015 
twenty-eight patients who received adjuvant RT after breast 
conserving surgery were studied. The patients' subjective 
feeling of fatigue intensity was measured according to with 
two standardized self-assessment instruments the Fatigue 
Assessment Questionnaire (FAQ) and a visual analog scale 
(VAS) on fatigue intensity before the start and weekly during 
RT, as well as 14 days and 3-6 and 12 months after RT. In 
addition, a differential blood cell count and the serum levels 
of the cytokines- IL1-b,, IL-6, and TNF-a, were determined in 
parallel to the fatigue assessments. 
 
